---
title: Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion
  and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple
  Myeloma
date: '2024-02-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38402374/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240225170529&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: Effectiveness of talquetamab for both schedules was significantly
  better than RWPC for ORR, ≥ VGPR, ≥ CR, PFS, OS, and TTNT, highlighting its clinical
  benefit for patients with TCE ...'
disable_comments: true
---
CONCLUSION: Effectiveness of talquetamab for both schedules was significantly better than RWPC for ORR, ≥ VGPR, ≥ CR, PFS, OS, and TTNT, highlighting its clinical benefit for patients with TCE ...